The 3-month PFS was significantly improved with the addition of ziv-aflibercept in patients who had platinum-refractory disease ( 27 % v 10 % ; P = .02 ) but not in patients with platinum-sensitive disease ( 24 % v 15 % ; P = .22 ) .